Home › B-Cell Lymphoma › Texas › Houston
Pag-aaral pangklinika para sa B-Cell Lymphoma sa Houston, TX
16 pag-aaral para sa B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Houston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Nagre-recruitPhase 1
- The University of Texas M D Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Nagre-recruitPhase 3
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Nagre-recruitPhase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Nagre-recruitPhase 2
- MD Anderson Cancer Center, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Nagre-recruitPhase 3
- Md Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
- Texas Children's Hospital, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Nagre-recruitPhase 1/2
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Nagre-recruitPhase 2
- Research Site, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Nagre-recruitPhase 2
- M D Anderson Cancer Center, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Nagre-recruitPhase 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Nagre-recruitPhase 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Nagre-recruitPhase 1/2
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Nagre-recruitPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
Nagre-recruitPhase 1
- MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Nagre-recruitPhase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Pag-aaral para sa B-Cell Lymphoma sa ibang lungsod
- New York City, NY17 pag-aaral
- Chicago, IL13 pag-aaral
- Nashville, TN12 pag-aaral
- Philadelphia, PA11 pag-aaral
- Rochester, MN10 pag-aaral
- Milwaukee, WI10 pag-aaral
- Boston, MA10 pag-aaral
- Baldwin Park, CA9 pag-aaral
- Cleveland, OH8 pag-aaral
- Salt Lake City, UT8 pag-aaral
- Seattle, WA8 pag-aaral
- Pittsburgh, PA7 pag-aaral
Iba pang pag-aaral sa Houston
- Non-Small Cell Lung Cancer143 pag-aaral
- Kanser sa Suso126 pag-aaral
- Kanser (lahat ng uri)124 pag-aaral
- Colorectal Cancer101 pag-aaral
- Metastatic Cancer100 pag-aaral
- Kanser sa Ovary90 pag-aaral
- Acute Myeloid Leukemia88 pag-aaral
- Kanser sa Baga78 pag-aaral
- Kanser sa Prostate73 pag-aaral
- Kanser ng Endometrium69 pag-aaral
- Melanoma61 pag-aaral
- Kanser sa Pancreas59 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.